Seelos Therapeutics Balance Sheet Health
Financial Health criteria checks 0/6
Seelos Therapeutics has a total shareholder equity of $-28.1M and total debt of $10.1M, which brings its debt-to-equity ratio to -35.9%. Its total assets and total liabilities are $2.4M and $30.5M respectively.
Key information
-35.9%
Debt to equity ratio
US$10.11m
Debt
| Interest coverage ratio | n/a |
| Cash | US$294.00k |
| Equity | -US$28.13m |
| Total liabilities | US$30.51m |
| Total assets | US$2.38m |
Recent financial health updates
Recent updates
Seelos: Data This Year Is Critical
Oct 04Seelos wins Parkinson’s research grant for gene therapy program
Aug 24Seelos: FDA Action Makes It Highly Attractive
Dec 22Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains
Oct 01We're Hopeful That Seelos Therapeutics (NASDAQ:SEEL) Will Use Its Cash Wisely
Aug 18
Seelos: Superior Data, But Early Stage
Jun 09Financial Position Analysis
Short Term Liabilities: SEEL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: SEEL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: SEEL has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: SEEL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: SEEL's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if SEEL's interest payments on its debt are well covered by EBIT.